To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

Recruiting now · Not applicable

Conditions studied: Recurrent Ovarian Cancer

In brief

The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.

Key facts

Study ID

NCT07651124

Run by

Yong Wha Moon

People needed

6

Starts

2025-04-01

Expected to finish

2027-06-30

Last updated by the study team

2026-06-16

Who can join

Age: 20 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Recurrent ovarian cancer
• There is a cancerous lesion that can be removed by biopsy or surgery.

You may not qualify if…

• Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
• Patient deemed unsuitable by the principal investigator

Where it is running

• Bundang CHA Medical Center — Gyeonggi-do, Bundang-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.